Responsiveness and Minimal Clinically Important Difference of the Motor Function Measure in Collagen VI-Related Dystrophies and Laminin Alpha2-Related Muscular Dystrophy.
Disability evaluation
Muscular dystrophies
Rehabilitation
Journal
Archives of physical medicine and rehabilitation
ISSN: 1532-821X
Titre abrégé: Arch Phys Med Rehabil
Pays: United States
ID NLM: 2985158R
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
23
06
2020
revised:
16
09
2020
accepted:
01
10
2020
pubmed:
10
11
2020
medline:
20
4
2021
entrez:
9
11
2020
Statut:
ppublish
Résumé
To investigate the responsiveness of the motor function measure (MFM) and determine the minimal clinically important difference (MCID) in individuals with 2 common types of congenital muscular dystrophy (CMD). Observational, prospective, single center, cohort study. National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). Individuals (N=44) with collagen VI-related dystrophies (COL6-RD, n=23) and 21 individuals laminin alpha2-related muscular dystrophy (LAMA2-RD, n=21) enrolled in a 4-year longitudinal natural history study. Not applicable. Responsiveness of the MFM-32 and the Rasch-scaled MFM-25 and the MCID of the MFM-32 determined from a patient-reported anchor with 2 different methods, within-patient and between-patient. The original MFM-32 and Rasch-scaled MFM-25 performed similarly overall in both the COL6-RD and LAMA2-RD populations, with all subscores (D1, standing and transfers; D2, axial and proximal; D3, distal) showing a significant decrease over time, except MFM D1 and D3 for LAMA2-RD. The MFM D1 subscore was the most sensitive to change for ambulant individuals, whereas the MFM D2 subscore was the most sensitive to change for nonambulant individuals. The MCID for the MFM-32 total score was calculated as 2.5 and 3.9 percentage points according to 2 different methods. The MFM showed strong responsiveness in individuals with LAMA2-RD and COL6-RD. Because a floor effect was identified more prominently with the Rasch-Scaled MFM-25, the use of the original MFM-32 as a quantitative variable with the assumption of scale linearity appears to be a good compromise. When designing clinical trials in congenital muscular dystrophies, the use of MCID for MFM should be considered to determine if a given intervention effects show not only a statistically significant change but also a clinically meaningful change.
Identifiants
pubmed: 33166523
pii: S0003-9993(20)31214-4
doi: 10.1016/j.apmr.2020.10.116
pmc: PMC10363856
mid: NIHMS1865249
pii:
doi:
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
604-610Subventions
Organisme : Intramural NIH HHS
ID : Z99 CL999999
Pays : United States
Informations de copyright
Copyright © 2020 American Congress of Rehabilitation Medicine. All rights reserved.
Références
Qual Life Res. 1995 Aug;4(4):293-307
pubmed: 7550178
Neuromuscul Disord. 2011 Jul;21(7):513-22
pubmed: 21641800
J Clin Epidemiol. 2010 May;63(5):524-34
pubmed: 19926446
Muscle Nerve. 2013 Sep;48(3):357-68
pubmed: 23674289
PLoS Curr. 2013 Jul 08;5:
pubmed: 23867975
Int J Integr Care. 2002;2:e15
pubmed: 16896390
Neuromuscul Disord. 2015 Jan;25(1):43-54
pubmed: 25307854
N Engl J Med. 2017 Nov 2;377(18):1723-1732
pubmed: 29091570
J Clin Epidemiol. 1989;42(5):403-8
pubmed: 2659745
Arch Phys Med Rehabil. 2014 Nov;95(11):2086-95
pubmed: 24973498
Arthritis Res Ther. 2015 Jun 03;17:143
pubmed: 26036334
Expert Rev Pharmacoecon Outcomes Res. 2011 Apr;11(2):171-84
pubmed: 21476819
J Clin Epidemiol. 2007 Jan;60(1):34-42
pubmed: 17161752
Neuromuscul Disord. 2005 Jul;15(7):463-70
pubmed: 16106528
Dev Med Child Neurol. 2013 Nov;55(11):1046-52
pubmed: 23909763
Arch Phys Med Rehabil. 2012 Dec;93(12):2251-6.e1
pubmed: 22705238
J Clin Epidemiol. 2008 Feb;61(2):102-9
pubmed: 18177782
Dev Med Child Neurol. 2008 Dec;50(12):918-25
pubmed: 19046185
Arch Phys Med Rehabil. 2013 Aug;94(8):1555-61
pubmed: 23380348
J Rehabil Med. 2011 Sep;43(9):770-5
pubmed: 21826385
Health Qual Life Outcomes. 2006 Aug 22;4:54
pubmed: 16925807
J Clin Epidemiol. 1997 Aug;50(8):869-79
pubmed: 9291871
J Chronic Dis. 1985;38(1):27-36
pubmed: 3972947
PLoS One. 2010 Aug 19;5(8):e12140
pubmed: 20808854
Neurology. 2019 Nov 19;93(21):e1932-e1943
pubmed: 31653707
Neuromuscul Disord. 2004 Oct;14(10):635-49
pubmed: 15351421
Arch Phys Med Rehabil. 1989 Nov;70(12):857-60
pubmed: 2818162